TB Biosciences, a life sciences firm commercialising tuberculosis detection kits, receives $1.5m in series A funding.

Life sciences firm TB Biosciences (TBB), which is commercialising tuberculosis detection kits developed at the New York University (NYU) School of Medicine, has received $1.5m in series A backing.

NYU Innovation Venture Fund participated in the round, which was led by venture firm Originate Ventures. The funding adds to National Institute of Health funding, bringing the total backing TBB to in excess of $2.5m.

The financing will be used to support product development and clinical trials. It aims to provide…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?